Estimation of the standardized risk difference and ratio in a competing risks framework: Application to injection drug use and progression to AIDS after initiation of antiretroviral therapy

American Journal of Epidemiology

Volumn 181, Issue 4, 2015, Pages 238-245

  Cole, Stephen R ^a   Lau, Bryan ^b   Eron, Joseph J ^c   Brookhart, M Alan ^a   Kitahata, Mari M ^d   Martin, Jeffrey N ^e   Mathews, William C ^f   Mugavero, Michael J ^g  

^a IL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

AIDS; Cohort study; Competing risks; HIV; Survival function

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BOOTSTRAPPING; COHORT ANALYSIS; DRUG; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; PRECISION; RISK ASSESSMENT; SURVIVAL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; AIDS PATIENT; ANTIVIRAL THERAPY; ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT PRECISION; MORTALITY; PROBABILITY; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; STANDARDIZED RISK DIFFERENCE; STANDARDIZED RISK RATIO; TIME TO TREATMENT; UNITED STATES; ACQUIRED IMMUNODEFICIENCY SYNDROME; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; ETHNOLOGY; FOLLOW UP; HISPANIC; MATHEMATICAL COMPUTING; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; SURVIVAL RATE;

UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; INCIDENCE; MALE; MATHEMATICAL COMPUTING; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL RATE; UNITED STATES;

EID: 84938968143     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu122     Document Type: Article

References (33)

1. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160(4):301-305.
2. Hernán MA. The hazards of hazard ratios. Epidemiology. 2010; 21(1):13-15.
3. Toh S, Hernández-Díaz S, Logan R, et al. Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. Epidemiology. 2010;21(4):528-539.
4. Robins JM, Morgenstern H. The foundations of confounding in epidemiology. Comput Math Appl. 1987;14(9-12):869-916.
5. Greenland S. Absence of confounding does not correspond to collapsibility of the rate ratio or rate difference. Epidemiology. 1996;7(5):498-501.
6. Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol. 1981;114(4):593-603.
7. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244-256.
8. Robins JM, Greenland S. Comment on: causal inference without counterfactuals. JASA. 2000;95(450):431-435.
9. Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies. Biometrics. 1990;46(3):813-826.
10. Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37(5):948-955.
11. Cox DR, Oakes D. Analysis of Survival Data. London, United Kingdom: Chapman and Hall; 1984.
12. Bekaert M, Vansteelandt S, Mertens K. Adjusting for time-varying confounding in the subdistribution analysis of a competing risk. Lifetime Data Anal. 2010;16(1):45-70.
13. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer; 2003.
14. Howe CJ, Cole SR, Westreich DJ, et al. Splines for trend analysis and continuous confounder control. Epidemiology. 2011;22(6):874-875.
15. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6): 656-664.
16. Prentice RL, Kalbfleisch JD, Peterson AV Jr, et al. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554.
17. SAS Institute. Estimating and plotting cumulative-incidence functions using the CUMINCID macro. Cary, NC: SAS Institute, Inc.; 2013. http://support.sas.com/kb/30/511.html. Accessed November 12, 2013.
18. Hernán MA, VanderWeele TJ. Compound treatments and transportability of causal inference. Epidemiology. 2011;22(3): 368-377.
19. Westreich D, Cole SR. Invited commentary: positivity in practice. Am J Epidemiol. 2010;171(6):674-677.
20. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006; 60(7):578-586.
21. Hernán MA, Cole SR. Invited commentary: causal diagrams and measurement bias. Am J Epidemiol. 2009;170(8): 959-962.
22. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35(1): 46-51.
23. Qian HZ, Stinnette SE, Rebeiro PF, et al. The relationship between injection and noninjection drug use and HIV disease progression. J Subst Abuse Treat. 2011;41(1): 14-20.
24. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology. 2009;20(6):880-883.
25. Spiegelman D. Approaches to uncertainty in exposure assessment in environmental epidemiology. Annu Rev Public Health. 2010;31:149-163.
26. Cole SR, Chu H, Greenland S. Multiple-imputation for measurement-error correction. Int J Epidemiol. 2006;35(4): 1074-1081.
27. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177(4):292-298.
28. Grambauer N, Schumacher M, Dettenkofer M, et al. Incidence densities in a competing events analysis. Am J Epidemiol. 2010; 172(9):1077-1084.
29. Rothman KJ, Greenland S, Lash T. Modern Epidemiology. 3rd ed. New York, NY: Lippincott-Raven; 2008.
30. Kraemer HC. Events per person-time (incidence rate): A misleading statistic? Stat Med. 2009;28(6):1028-1039.
31. Allignol A, Schumacher M, Wanner C, et al. Understanding competing risks: a simulation point of view. BMC Med Res Methodol. 2011;11:86.
32. Kaufman JS. Marginalia: comparing adjusted effect measures. Epidemiology. 2010;21(4):490-493.
33. Cole SR, Richardson DB, Chu H, et al. Analysis of occupational asbestos exposure and lung cancer mortality using the G formula. Am J Epidemiol. 2013;177(9):989-996.